Compare · MNKD vs MRK
MNKD vs MRK
Side-by-side comparison of MannKind Corporation (MNKD) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MNKD and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $314.90B, about 252.9x MNKD ($1.25B).
- Over the past year, MNKD is up 7.3% and MRK is up 59.4% - MRK leads by 52.1 points.
- MRK has been more active in the news (14 items in the past 4 weeks vs 8 for MNKD).
- MRK has more recent analyst coverage (25 ratings vs 14 for MNKD).
- Company
- MannKind Corporation
- Merck & Company Inc.
- Price
- $4.03-0.49%
- $127.48-0.14%
- Market cap
- $1.25B
- $314.90B
- 1M return
- +4.01%
- +10.60%
- 1Y return
- +7.33%
- +59.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 8
- 14
- Recent ratings
- 14
- 25
MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-Ã inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest MNKD
- Chief Financial Officer Prentiss Christopher B covered exercise/tax liability with 22,247 shares, decreasing direct ownership by 7% to 318,668 units (SEC Form 4)
- Pres, Endocrine Business Unit Marasco Dominic covered exercise/tax liability with 3,623 shares, decreasing direct ownership by 1% to 343,398 units (SEC Form 4)
- Chief People & Workpl Officer Tross Stuart A converted options into 93,790 shares and covered exercise/tax liability with 65,808 shares, increasing direct ownership by 3% to 1,058,142 units (SEC Form 4)
- Chief Executive Officer Castagna Michael converted options into 350,260 shares and covered exercise/tax liability with 363,200 shares, decreasing direct ownership by 0.53% to 2,433,779 units (SEC Form 4)
- EVP Technical Operations Singh Sanjay R converted options into 70,550 shares and covered exercise/tax liability with 46,795 shares, increasing direct ownership by 5% to 478,966 units (SEC Form 4)
- EVP Genl Counsel & Secretary Thomson David covered exercise/tax liability with 98,426 shares, sold $97,641 worth of shares (24,109 units at $4.05) and converted options into 93,790 shares, decreasing direct ownership by 3% to 797,554 units (SEC Form 4)
- Director Binder Steven B. sold $213,089 worth of shares (52,485 units at $4.06), converted options into 93,790 shares and covered exercise/tax liability with 24,395 shares, increasing direct ownership by 2% to 824,918 units (SEC Form 4)
- MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
- Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
- MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
Latest MRK
- Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
- Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
- KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
- Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
- FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
- SEC Form 11-K filed by Merck & Company Inc.